FAPI PET Imaging: Ga-68 and F-18 Physics

Introduction

FAPI PET is a molecular imaging method that targets fibroblast activation protein (FAP) on cancer-associated fibroblasts, giving high tumor-to-background contrast without fasting and with very low uptake in brain, liver, pancreas, and the gastrointestinal tract. Instead of asking "where is glucose being consumed?" — the question fluorodeoxyglucose (FDG) answers — FAPI asks "where is the reactive tumor stroma?" For many cancers, that turns out to be a cleaner, more specific question.

Fibroblast activation protein is a serine protease that is strongly overexpressed on the cancer-associated fibroblasts that populate the stroma of the great majority of epithelial tumors, while being nearly undetectable in most normal adult tissues. ¹ A small-molecule FAP inhibitor (FAPI), coupled to a chelator and a PET radionuclide, therefore concentrates in tumor stroma and clears rapidly from background, producing images with excellent lesion conspicuity. ^{1, 2}

For the medical physicist and the nuclear medicine team, FAPI raises concrete questions: which radionuclide — generator-produced gallium-68 or cyclotron-produced fluorine-18 — and what does that choice do to image quality, logistics, dosimetry, and the theranostic future? This guide covers the biology briefly, then focuses on the physics, quantification, and quality control that make FAPI PET reliable. DRPS supports these programs through PET/CT and nuclear medicine physics and accreditation support.

Topic Explanation

The biological target

Solid tumors are not just malignant cells; they are an ecosystem. A large fraction of a tumor's volume is stroma — the connective-tissue scaffold — and the dominant cell type in that stroma is the cancer-associated fibroblast (CAF). CAFs express FAP at high levels, and FAP expression correlates with tumor growth, invasion, and a poorer prognosis in many cancers. Because normal adult fibroblasts express little FAP, a FAP-directed tracer has an unusually favorable target-to-background biology. ¹

FAPI compounds are quinoline-based inhibitors that bind the enzymatic pocket of FAP. Successive generations (FAPI-02, FAPI-04, FAPI-46, FAPI-74) improved tumor retention and pharmacokinetics. Each is built on a chelator — typically DOTA — that can hold a range of radiometals, which is the structural basis for both imaging and therapy. ^{1, 2}

Why it produces clean images

Three properties combine to give FAPI its high-contrast appearance:

High, specific tumor uptake driven by dense FAP expression on CAFs.
Rapid blood and background clearance, largely renal, so background falls quickly after injection.
Very low physiological uptake in brain, liver, pancreas, and much of the GI tract — precisely the regions where FDG's background can obscure disease. ^{1, 3}

The result is that small primary and metastatic lesions in the liver, pancreas, peritoneum, and brain — difficult on FDG — often stand out on FAPI. ^{1, 4}

Key Technical Principles

Two radionuclides, one molecule

The same FAPI molecule can be labeled with different PET radionuclides. The two clinically relevant choices have distinct physics.

Property	Gallium-68 (⁶⁸Ga)	Fluorine-18 (¹⁸F)
Production	⁶⁸Ge/⁶⁸Ga generator, on site	Cyclotron, central production
Half-life	67.7 min	109.8 min
Positron branching	≈ 89%	≈ 97%
Maximum positron energy	≈ 1.90 MeV	0.634 MeV
Relative positron range	Longer (slightly blurs resolution)	Shorter (sharper resolution)
Batch size / distribution	Limited per elution; local use	Large batches; can ship to satellites
Typical imaging window	~10–60 min post-injection	~10–60 min post-injection

Gallium-68 is attractive because a generator lets a site produce tracer without a cyclotron; its limitations are the short half-life, the finite activity per elution, and a longer positron range that marginally degrades spatial resolution. Fluorine-18 requires a cyclotron and radiochemistry but offers a longer half-life — enabling batch production and shipment to satellite sites — and a shorter positron range that yields crisper images. ¹ The biological target and the interpretation are the same; the differences are physical and logistical.

The positron-range effect on resolution

Spatial resolution in PET is limited partly by the distance a positron travels before it annihilates. A higher-energy positron travels farther, blurring the reconstructed point. Because gallium-68's positrons are more energetic than fluorine-18's, ⁶⁸Ga images carry an intrinsic resolution penalty. For most clinical FAPI reads this is modest, but it matters for small-lesion quantification and is one reason ¹⁸F-labeled FAPI tracers are of interest. For the broader treatment of this effect, see our post on PET spatial resolution and positron range.

Quantification: SUV and tumor-to-background ratio

FAPI images are read qualitatively and quantitatively. The standardized uptake value normalizes measured activity concentration to injected activity and body mass:

SUV_{b w} = \frac{C _{ROI} [ kBq/mL ]}{A _{inj} [ kBq ] / m [ g ]}

where $C_{ROI}$ is the decay-corrected activity concentration in the region of interest, $A_{inj}$ is the injected activity, and $m$ is body mass. Because FAPI background is so low, the tumor-to-background ratio (TBR) is often more informative than SUV alone:

TBR = \frac{SUV _{m a x} ( lesion )}{SUV _{mean} ( background )}

A lesion with $SUV_{m a x} = 8$ against a liver background of $SUV_{mean} = 1$ gives $TBR = 8$ — a contrast level FDG rarely achieves in the liver, where physiological background is much higher.

Worked example: decay during the uptake window

Because gallium-68 decays quickly, the activity available for imaging depends strongly on timing. Activity follows exponential decay:

A (t) = A_{0} e^{- λ t}, λ = \frac{ln 2}{T _{1/2}}

For ⁶⁸Ga ( $T_{1/2} = 67.7$ min), the fraction of injected activity remaining after a 15-minute uptake period is:

\frac{A ( 15 )}{A _{0}} = e^{- \frac{l n 2}{67.7} \times 15} = e^{- 0.154} \approx 0.86

so about 86% of the activity remains — favorable for early imaging. For ¹⁸F ( $T_{1/2} = 109.8$ min) after a 60-minute uptake:

\frac{A ( 60 )}{A _{0}} = e^{- \frac{l n 2}{109.8} \times 60} = e^{- 0.379} \approx 0.68

The longer ¹⁸F half-life is what makes centralized production and later imaging practical. Note that FAPI's fast pharmacokinetics allow diagnostic contrast early, which pairs naturally with gallium-68's short half-life.

Clinical Impact

Where FAPI outperforms FDG

FAPI PET has shown particular value in cancers that are poorly FDG-avid or that sit in high-FDG-background regions: pancreatic ductal adenocarcinoma, cholangiocarcinoma, hepatocellular carcinoma, gastric (especially signet-ring) carcinoma, certain sarcomas, and head-and-neck and brain lesions. ^{1, 3, 4} In sarcoma, reviews describe FAPI PET as a promising "pan-sarcoma" imaging approach because FAP is expressed across many histologic subtypes, offering complementary information to FDG for diagnosis, staging, and response assessment. ^{3, 5} In colorectal cancer, FAP expression is notably high in lymph-node and peritoneal metastases, where FAPI may improve detection of small-volume disease. ⁴

Workflow advantages

Beyond image contrast, FAPI offers practical benefits: no fasting, no blood-glucose management, and no need to keep diabetic patients waiting for glucose control. Uptake is rapid, so imaging can begin sooner after injection than the standard ~60-minute FDG uptake period. These are real throughput and patient-experience gains for a busy PET service. ¹

The theranostic dimension

Because FAPI carries a DOTA chelator, the same targeting molecule can hold a therapeutic radionuclide — lutetium-177 (β⁻), yttrium-90 (β⁻), or actinium-225 (α). This is the theranostic promise: use ⁶⁸Ga- or ¹⁸F-FAPI to identify and quantify FAP-expressing disease, then treat with a FAP-targeted radioligand. Preclinical work has directly compared ¹⁷⁷Lu-FAPI-46 and ²²⁵Ac-FAPI-46 in a pancreatic-cancer model, showing tumor suppression with both and highlighting that the optimal therapeutic radionuclide and molecule are still being refined. ⁶ FAP-targeted therapy remains investigational, but it is the reason FAPI is discussed as a platform rather than a single tracer. For the broader theranostic framework, see common PET and RPT isotopes.

Practical Optimization Tips

A FAPI PET program benefits from the same physics discipline as any quantitative PET service, with a few FAPI-specific points.

1. Fix the imaging timing

Because contrast develops early and radionuclide half-lives differ, define and document the uptake interval for your tracer and hold it constant so SUV and TBR are comparable across patients and over time.

2. Harmonize the scanner

Quantitative comparison across scanners or sites requires calibration and harmonization (for example, EARL-style approaches) so that SUV means the same thing everywhere. See EARL PET SUV harmonization and PET SUV quantification.

3. Account for the radionuclide in QC

Gallium-68 and fluorine-18 have different positron ranges and prompt-gamma characteristics; daily QC, the NEMA NU-2 performance baseline, and reconstruction settings should reflect the tracer actually used. See PET/CT NEMA NU-2 performance testing.

4. Verify tracer quality

Radiochemical purity and identity testing apply to FAPI as to any radiopharmaceutical; for generator-produced ⁶⁸Ga, confirm generator QC and breakthrough limits. See Ge-68/Ga-68 generator quality control.

5. Prefer TBR where background matters

In the liver, pancreas, and GI tract, report tumor-to-background ratio alongside SUV, since FAPI's low background is precisely where its diagnostic advantage lives.

Common pitfalls to avoid

Assuming FAPI uptake is cancer-specific. FAP is also expressed in benign fibrotic, inflammatory, and healing processes (e.g., recent surgery, arthritis, scar), which can cause false positives.
Comparing SUVs across un-harmonized scanners. Without calibration, SUV differences may be instrumental, not biological.
Ignoring the positron-range difference when quantifying small lesions on ⁶⁸Ga versus ¹⁸F.
Treating FAPI as FDG for logistics. Timing, half-life, and production model differ.
Overlooking the regulatory status. FAPI is investigational in the U.S.; confirm the pathway before clinical use.

Regulatory Considerations

FAPI PET sits at the intersection of radiopharmaceutical regulation, compounding standards, and PET accreditation, and its investigational status in the United States adds an extra layer. As of 2026, FAPI tracers are used under research or investigational-new-drug (IND) protocols rather than as FDA-approved routine agents, so facilities must confirm the regulatory basis for any FAPI use. ^{1, 2}

Key frameworks once a facility handles FAPI:

10 CFR Part 35 — Medical Use of Byproduct Material governs the medical use of reactor- and generator-produced radionuclides such as gallium-68 and any therapeutic FAP-targeted radioligands, including authorized-user requirements and, for therapy, written directives and patient release. Fluorine-18 and gallium-68 medical use fall under NRC or Agreement-State authority.
USP General Chapter <825> sets standards for the compounding, dispensing, and quality of positron-emission-tomography and other radiopharmaceuticals, applicable to FAPI preparation. See USP <825> radiopharmaceutical compounding.
SNMMI procedure guidance and ACR–AAPM PET/CT accreditation define the imaging quality, phantom QC, and physicist oversight expected of a quantitative PET service.

Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control rules, while Washington DC and Delaware are regulated directly by the NRC. A facility must confirm which authority issues its radioactive-material license and which requirements apply.

Frequently Asked Questions (FAQs)

What does FAPI PET actually target?

FAPI PET targets fibroblast activation protein (FAP), a serine protease that is highly expressed on cancer-associated fibroblasts in the stroma of most epithelial tumors but is nearly absent in normal adult tissue. The radiotracer is a small-molecule FAP inhibitor (FAPI) that binds FAP, so the PET signal maps tumor stroma rather than glucose metabolism.

How is FAPI PET different from FDG PET?

FDG images glucose metabolism and requires fasting and controlled blood glucose; it has high physiological uptake in brain, myocardium, and variable uptake in liver and bowel. FAPI images FAP on tumor stroma, needs no fasting or glucose control, has very low background in brain, liver, pancreas, and GI tract, and reaches diagnostic contrast quickly. FAPI often outperforms FDG in low-glucose-avid cancers such as pancreatic, cholangiocarcinoma, gastric signet-ring, and certain sarcomas.

What is the difference between Ga-68 FAPI and F-18 FAPI?

Ga-68 is produced from a germanium-68/gallium-68 generator on site, has a 67.7-minute half-life, and a longer positron range that slightly limits spatial resolution. F-18 is cyclotron-produced, has a 109.8-minute half-life that allows batch production and distribution to other sites, and a shorter positron range that gives sharper images. Both label the same FAPI molecule; the choice is logistical and physical rather than a change in the biological target.

Does FAPI PET require the patient to fast?

No. Because FAPI targets fibroblast activation protein rather than glucose metabolism, its uptake is not affected by blood glucose or insulin, so patients do not need to fast and diabetic patients do not need special glucose management. This is a practical workflow advantage over FDG.

Is FAPI PET FDA-approved and available for routine clinical use?

As of 2026, FAPI radiopharmaceuticals remain investigational in the United States and are used under research or investigational-new-drug protocols; none has full FDA approval for routine clinical use, though clinical adoption and trials are expanding rapidly. Facilities should confirm the regulatory pathway for any FAPI tracer before clinical use.

What is the theranostic potential of FAPI?

The FAPI molecule is attached to a DOTA chelator, which can hold an imaging radionuclide such as Ga-68 or F-18, or a therapeutic radionuclide such as Lu-177, Y-90, or Ac-225. That shared chemistry allows a theranostic pairing: image FAP expression to select and monitor patients, then treat with a FAP-targeted radioligand. FAP-targeted therapy is still investigational and under active study.

Key Takeaways

FAPI targets tumor stroma, not glucose. It binds fibroblast activation protein on cancer-associated fibroblasts, giving high, specific contrast.
Very low background in brain, liver, pancreas, and GI tract is FAPI's signature advantage, especially over FDG.
No fasting, rapid uptake simplify workflow and help diabetic patients.
Ga-68 vs F-18 is a physics/logistics choice: generator convenience and short half-life versus cyclotron batch production, longer half-life, and sharper resolution.
Report TBR with SUV where background matters; harmonize scanners for quantitative comparability.
FAP is not cancer-exclusive — fibrosis, inflammation, and healing can cause false positives.
Theranostic platform: the DOTA chelator enables Lu-177/Y-90/Ac-225 FAP-targeted therapy, still investigational.

Conclusion

FAPI PET is one of the most promising developments in oncologic molecular imaging because it changes the question the scan answers — from glucose metabolism to tumor stroma — and does so with unusually clean images. Its low background in the liver, pancreas, brain, and GI tract addresses exactly the regions where FDG struggles, and its stroma-targeting biology extends PET into cancers that were poorly served by metabolic imaging.

For the physics team, FAPI is a study in trade-offs: gallium-68's generator convenience against fluorine-18's resolution and distribution, SUV against tumor-to-background ratio, and imaging against a theranostic future built on the same molecule. Getting those trade-offs right — with disciplined timing, scanner harmonization, tracer QC, and clear-eyed attention to FAP's non-cancer expression — is what turns an exciting tracer into a reliable clinical tool.

How DRPS Can Help

Diagnostic Radiation Physics Services supports PET/CT programs adopting new tracers like FAPI with PET/CT and nuclear medicine physics services: scanner calibration and SUV harmonization, NEMA NU-2 performance baselines, daily QC review, reconstruction optimization for the radionuclide in use, radiopharmaceutical and generator QC review, and accreditation support for ACR PET/CT. We also provide medical physicist consulting for programs planning theranostic services.

DRPS serves facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

Related Resources

References

Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology. 2023;306(2):e220749. doi:10.1148/radiol.220749. PubMed
Dendl K, Koerber SA, Kratochwil C, et al. FAP and FAPI-PET/CT in malignant and non-malignant diseases: a perfect symbiosis? Cancers (Basel). 2021;13(19):4946. doi:10.3390/cancers13194946. PubMed
Kessler L. Fibroblast activation protein inhibitor (FAPI)-PET imaging in sarcoma. PET Clin. 2023;18(3):353-359. doi:10.1016/j.cpet.2023.03.001. PubMed
Strating E, van de Loo A, Elias S, Lam M, Kranenburg O. Fibroblast activation protein inhibitor-PET imaging in colorectal cancer. PET Clin. 2023;18(3):325-335. doi:10.1016/j.cpet.2023.02.003. PubMed
Giammarile F, Knoll P, Paez D, Estrada Lobato E, Calapaquí Terán AK, Delgado Bolton RC. Fibroblast activation protein inhibitor (FAPI) PET imaging in sarcomas: a new frontier in nuclear medicine. Semin Nucl Med. 2024;54(3):340-344. doi:10.1053/j.semnuclmed.2024.01.001. PubMed
Liu Y, Watabe T, Kaneda-Nakashima K, et al. Fibroblast activation protein targeted therapy using [¹⁷⁷Lu]FAPI-46 compared with [²²⁵Ac]FAPI-46 in a pancreatic cancer model. Eur J Nucl Med Mol Imaging. 2022;49(3):871-880. doi:10.1007/s00259-021-05554-2. PubMed
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
United States Pharmacopeia. USP General Chapter <825>: Radiopharmaceuticals — Preparation, Compounding, Dispensing, and Repackaging. usp.org